Stroke is a major contributor to both death and disability in Europe. Thrombectomy, a crucial treatment for severe strokes caused by large vessel blockages, faces significant challenges in development and implementation. With a mere 10% success rate in introducing new stroke treatments, there’s a pressing need for faster, more efficient, and cost-effective solutions. inSteps introduces an advanced in-silico modelling platform designed for developing, testing, and evaluating endovascular devices. inSteps offers a solution to accelerate the adoption of life-saving treatments for millions of people affected by acute ischemic strokes, thereby addressing a critical healthcare need.

inSteps' unique advanced in-silico modelling platform is a sophisticated computer-based system designed to simulate and model complex medical processes and scenarios, such as stroke and its treatment. The platform is employed in service of device manufacturers of stent-retrievers to test different stent designs across various patient anatomies and clot types before embarking on costly clinical trials. Our in-silico models enable the thorough evaluation and improved implementation of novel treatments for different sub-populations.

Born from the University of Amsterdam,  inSteps was founded in 2023 by Prof. Henk Marquering, Dr. Praneeta Konduri, Dr. Nerea Arrarte Terreros and Dr. Thomas Kerbusch. They hail from the Departments of Radiology & Nuclear Medicine, Biomedical Engineering & Physics at Amsterdam UMC-AMC.  

The mission of inSteps is to support device manufacturers (business-to-business services) in designing, testing, and launching new stroke treatment devices to provide acute ischemic stroke patients with better life-saving treatments. 
The company offers 4 different modules: 
Module 1 – Virtual stroke population.  
Module 2 – Finite element thrombectomy models.  
Module 3 – Stroke disease model.  
Module 4 – In-silico trial platform

inSteps BV

Org chart

Teams

Offices